Double‐blind, placebo‐controlled study of lurasidone monotherapy for the treatment of bipolar I depression

AIM: Previous studies conducted primarily in the USA and Europe have demonstrated the efficacy and safety of lurasidone 20–120 mg/day for the treatment of bipolar I depression. The aim of the current study was to evaluate the efficacy and safety of lurasidone monotherapy for the treatment of bipolar...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:Psychiatry Clin Neurosci
Egile Nagusiak: Kato, Tadafumi, Ishigooka, Jun, Miyajima, Mari, Watabe, Kei, Fujimori, Tomohiro, Masuda, Takahiro, Higuchi, Teruhiko, Vieta, Eduard
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: John Wiley & Sons Australia, Ltd 2020
Gaiak:
Regular Articles
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC7756283/
https://ncbi.nlm.nih.gov/pubmed/32827348
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/pcn.13137
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak